Catechol-O-Methyltransferase val158met Polymorphism Predicts Placebo Effect in Irritable Bowel Syndrome

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Hall, Kathryn T ^a   Lembo, Anthony J ^a   Kirsch, Irving ^a,b   Ziogas, Dimitrios C ^c   Douaiher, Jeffrey ^d   Jensen, Karin B ^a,e   Conboy, Lisa A ^a   Kelley, John M ^a,e,f   Kokkotou, Efi ^a   Kaptchuk, Ted J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

^c UNIVERSITY OF ATHENS   (Greece)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f ENDICOTT COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CATECHOL METHYLTRANSFERASE;

ACUPUNCTURE; ADULT; ARTICLE; DOCTOR PATIENT RELATION; DRUG RESPONSE; FEMALE; GENETIC MARKER; HEALTH CARE PERSONNEL; HOMOZYGOTE; HUMAN; IRRITABLE BOWEL SYNDROME SYMPTOM SEVERITY SCALE; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SINGLE NUCLEOTIDE POLYMORPHISM; SUPPORT GROUP; TREATMENT OUTCOME;

ADULT; AMINO ACID SUBSTITUTION; CATECHOL O-METHYLTRANSFERASE; FEMALE; GENOTYPE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PLACEBO EFFECT; PLACEBOS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867862609     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048135     Document Type: Article

References (57)

1. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F, (2010) Biological, clinical, and ethical advances of placebo effects. Lancet 375: 686-695.
2. Zubieta JK, Stohler CS, (2009) Neurobiological mechanisms of placebo responses. Annals of the New York Academy of Sciences 1156: 198-210.
3. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, et al. (2007) Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 55: 325-336.
4. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, et al. (2008) Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Archives of general psychiatry 65: 220-231.
5. Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, et al. (2005) Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. The Journal of neuroscience: the official journal of the Society for Neuroscience 25: 7754-7762.
6. Meyer-Lindenberg A, Kohn PD, Kolachana B, Kippenhan S, McInerney-Leo A, et al. (2005) Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nature neuroscience 8: 594-596.
7. Yavich L, Forsberg MM, Karayiorgou M, Gogos JA, Mannisto PT, (2007) Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. The Journal of neuroscience: the official journal of the Society for Neuroscience 27: 10196-10209.
8. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, et al. (1996) Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6: 243-250.
9. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, et al. (1995) Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34: 4202-4210.
10. Diamond A, (2007) Consequences of variations in genes that affect dopamine in prefrontal cortex. Cerebral cortex 17 (Suppl 1):: i161-170.
11. Solis-Ortiz S, Perez-Luque E, Morado-Crespo L, Gutierrez-Munoz M, (2010) Executive functions and selective attention are favored in middle-aged healthy women carriers of the Val/Val genotype of the catechol-o-methyltransferase gene: a behavioral genetic study. Behavioral and brain functions: BBF 6: 67.
12. Winterer G, Goldman D, (2003) Genetics of human prefrontal function. Brain research Brain research reviews 43: 134-163.
13. Truong T, Kilpatrick L, Naliboff B, Dandekar S, Papp J, et al. (2009) COMT Genetic Polymorphism Is Associated with Alterations in Attentional Processing in Patients with IBS and Other Functional Pain Syndromes. Gastroenterology 136: A-74, 2009) 136: A-74.
14. Massat I, Kocabas NA, Crisafulli C, Chiesa A, Calati R, et al. (2011) COMT and age at onset in mood disorders: a replication and extension study. Neuroscience letters 498: 218-221.
15. Doll BB, Hutchison KE, Frank MJ, (2011) Dopaminergic genes predict individual differences in susceptibility to confirmation bias. The Journal of neuroscience: the official journal of the Society for Neuroscience 31: 6188-6198.
16. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, et al. (2005) Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Human molecular genetics 14: 135-143.
17. Dai F, Belfer I, Schwartz CE, Banco R, Martha JF, et al. (2010) Association of catechol-O-methyltransferase genetic variants with outcome in patients undergoing surgical treatment for lumbar degenerative disc disease. The spine journal: official journal of the North American Spine Society 10: 949-957.
18. Tchivileva IE, Lim PF, Smith SB, Slade GD, Diatchenko L, et al. (2010) Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. Pharmacogenetics and genomics 20: 239-248.
19. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, et al. (2003) COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299: 1240-1243.
20. Loggia ML, Jensen K, Gollub R, Wasan AD, Edwards R, et al. (2011) The catechol-O-methyltransferase(COMT) val158met polymorphism affects brain responses to repeated painful stimuli. PloS one 6: e27764.
21. Jensen KB, Lonsdorf TB, Schalling M, Kosek E, Ingvar M, (2009) Increased sensitivity to thermal pain following a single opiate dose is influenced by the COMT val(158)met polymorphism. PloS one 4: e6016.
22. Rakvag TT, Klepstad P, Baar C, Kvam TM, Dale O, et al. (2005) The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116: 73-78.
23. Drossman DA, Camilleri M, Mayer EA, Whitehead WE, (2002) AGA technical review on irritable bowel syndrome. Gastroenterology 123: 2108-2131.
24. Saito YA, Schoenfeld P, Locke GR 3rd (2002) The epidemiology of irritable bowel syndrome in North America: a systematic review. The American journal of gastroenterology 97: 1910-1915.
25. Chang L, Drossman DA, (2010) Rome Foundation Endpoints and Outcomes Conference 2009: Optimizing Clinical Trials in FGID. The American journal of gastroenterology 105: 722-730.
26. Mayer EA, Bushnell MC, International Association for the Study of Pain (2009) Functional pain syndromes: presentation and pathophysiology. Seattle: IASP Press. xviii, 580 p.
27. Dorn SD, Kaptchuk TJ, Park JB, Nguyen LT, Canenguez K, et al. (2007) A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterology and motility: the official journal of the European Gastrointestinal Motility Society 19: 630-637.
28. Ford AC, Moayyedi P, (2010) Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Alimentary pharmacology & therapeutics 32: 144-158.
29. Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, et al. (2005) The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterology and motility: the official journal of the European Gastrointestinal Motility Society 17: 332-340.
30. Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, et al. (2008) Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 336: 999-1003.
31. Conboy LA, Macklin E, Kelley J, Kokkotou E, Lembo A, et al. (2010) Which patients improve: characteristics increasing sensitivity to a supportive patient-practitioner relationship. Social science & medicine 70: 479-484.
32. Francis CY, Morris J, Whorwell PJ, (1997) The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Alimentary pharmacology & therapeutics 11: 395-402.
33. Mangel AW, Hahn BA, Heath AT, Northcutt AR, Kong S, et al. (1998) Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. The Journal of international medical research 26: 76-81.
34. Gordon S, Ameen V, Bagby B, Shahan B, Jhingran P, et al. (2003) Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy. Digestive diseases and sciences 48: 1317-1323.
35. Lembo T, Wright RA, Bagby B, Decker C, Gordon S, et al. (2001) Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. The American journal of gastroenterology 96: 2662-2670.
36. Campbell DT, Kenny DA (1999) A primer on regression artifacts. New York: Guilford Press. xxi, 202 p.
37. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, et al. (2006) Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 314: 1930-1933.
38. Gaunt TR, Rodriguez S, Zapata C, Day IN, (2006) MIDAS: software for analysis and visualisation of interallelic disequilibrium between multiallelic markers. BMC bioinformatics 7: 227.
39. Gaunt TR, Rodriguez S, Day IN, (2007) Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'. BMC bioinformatics 8: 428.
40. Furmark T, Appel L, Henningsson S, Ahs F, Faria V, et al. (2008) A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. The Journal of neuroscience: the official journal of the Society for Neuroscience 28: 13066-13074.
41. Leuchter AF, McCracken JT, Hunter AM, Cook IA, Alpert JE, (2009) Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. Journal of clinical psychopharmacology 29: 372-377.
42. Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, et al. (2007) Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 32: 1011-1020.
43. Farrell SM, Tunbridge EM, Braeutigam S, Harrison PJ, (2012) COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biological psychiatry 71: 538-544.
44. Giakoumaki SG, Roussos P, Bitsios P, (2008) Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 33: 3058-3068.
45. Roussos P, Giakoumaki SG, Bitsios P, (2009) Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c/g polymorphism. Biological psychiatry 66: 997-1004.
46. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, et al. (2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 98: 6917-6922.
47. Schmack K, Schlagenhauf F, Sterzer P, Wrase J, Beck A, et al. (2008) Catechol-O-methyltransferase val158met genotype influences neural processing of reward anticipation. NeuroImage 42: 1631-1638.
48. Goldman-Rakic PS, (1998) The cortical dopamine system: role in memory and cognition. Advances in pharmacology 42: 707-711.
49. Williams GV, Goldman-Rakic PS, (1995) Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376: 572-575.
50. Kaptchuk TJ, Kelley JM, Deykin A, Wayne PM, Lasagna LC, et al. (2008) Do "placebo responders" exist? Contemporary clinical trials 29: 587-595.
51. Shapiro AK, Shapiro E (1997) The powerful placebo: from ancient priest to modern physician. Baltimore: Johns Hopkins University Press. xi, 280 p.
52. Whalley B, Hyland ME, Kirsch I, (2008) Consistency of the placebo effect. Journal of psychosomatic research 64: 537-541.
53. Kelley JM, Lembo AJ, Ablon JS, Villanueva JJ, Conboy LA, et al. (2009) Patient and practitioner influences on the placebo effect in irritable bowel syndrome. Psychosomatic medicine 71: 789-797.
54. Miller FG, Colloca L, Kaptchuk TJ, (2009) The placebo effect: illness and interpersonal healing. Perspectives in biology and medicine 52: 518-539.
55. Wechsler ME, Kelley JM, Boyd IO, Dutile S, Marigowda G, et al. (2011) Active albuterol or placebo, sham acupuncture, or no intervention in asthma. The New England journal of medicine 365: 119-126.
56. Branch WT, Arky RA, Woo B, Stoeckle JD, Levy DB, et al. (1991) Teaching medicine as a human experience: a patient-doctor relationship course for faculty and first-year medical students. Annals of internal medicine 114: 482-489.
57. Egnew TR, Wilson HJ, (2011) Role modeling the doctor-patient relationship in the clinical curriculum. Family medicine 43: 99-105.